Liquid naloxone spray
The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
1. A liquid nasal spray formulation comprising from about 8% to about 16% w/w naloxone or a pharmaceutically acceptable salt thereof, from about 20% to about 50% w/w ethanol and water, wherein w/w denotes weight by total weight of the formulation, wherein naloxone or the pharmaceutically acceptable salt thereof is at a dosage from about 8 to about 16 milligrams, and wherein intranasal administration of the formulation to a mammalian subject in a fasted state exhibits a mean plasma concentration one hour after administration of from about 6.2 to about 14.1 nanograms per milliliter (ng/ml).